Background-The association between coffee drinking and risk of coronary heart disease remains controversial despite many epidemiological studies. A metaanalysis was carried out on these studies to resolve some of the uncertainties. Particular attention-was paid to details of study design. Methods-Eight case-control studies and 15 cohort studies were analysed. Weighted, fixed effects linear regression of log relative risks (or odds ratios) was used to pool the study results. The pooling procedures were performed separately by study design, sex, coronary heart disease end points, smoking habit, and period of study. Results-The pooled case-control odds ratio (for the effect of drinking five cups of coffee/day v none) was 1-63 (95% confidence interval (95% CI) 1 50 to 1.78). The pooled cohort study relative risk (five cupslday v none) was 1 05 (95% CI 099 to 1.12). The discrepancy between the pooled case-control and cohort study results could not be attributed to differences in the end points chosen, period of study, or to confounding by smoking status or sex.
The association between coffee drinking and risk of coronary heart disease (CHD) remains controversial despite many epidemiological studies. A relation of coffee drinking to CHD was first suspected because of the role of caffeine in inducing cardiac arrhythmias, and increases in plasma renin activity, catecholamine concentrations, and blood pressure.'2 Although it seems now that these effects are not clinically significant in most habitual drinkers,' renewed concern has arisen from cross sectional findings of an association between coffee drinking and serum total cholesterol concentrations. 49 The inconsistent findings of epidemiological studies-for example, comparing the results of LaCroix et alt' with those of Grobbee et a' '-have resulted in conflicting policy advice.'2 To resolve some of the existing uncertainties, we applied the techniques of meta-analysis to all published epidemiological studies of coffee consumption and CHD, paying particular attention to details of study design.
Patients and methods

METHODS
Selection of studies Epidemiological studies of coffee consumption and heart disease were identified by a computer aided literature search, as well as by bibliographical searches of review articles"3 and previous meta-analysis.'2 14 Early case-control studies'5-"7 were excluded from the meta-analysis as these reports included insufficient information to permit calculations of relative risks and SEMs. Two studies'81 9 were excluded on the basis that they examined prevalence of heart disease only. Wherever more than one published report was generated with the same cohort or case-control study,2'2' the most updated data were included in the metaanalysis.242' In the case of the Framingham study the original report by Dawber et at'5 examined non-fatal myocardial infarction as an end point, whereas the update of the same cohort29 provided data on total cardiovascular disease mortality (including angina, congestive heart failure, and intermittent claudication). We used the more recent Framingham data29 in the overall pooled analysis, although we included the earlier report28 in a subanalysis of studies that used myocardial infarction as an end point. Similarly, in the case of the Seventh Day Adventists' cohort, the original report by Snowdon et a?3 assessed fatal CHD in men and women, whereas the updated report27 presented data for men only. We used the more recent data27 in the overall pooled analysis, but included the earlier report23 subanalyses broken down by sex. A total of eight case-control studies25 3037 (appendix 1) and 15 cohort studies'01 124 26 27 29 37'4 (appendix 2) were used in the meta-analysis.
Statistical methods
The pooled method involved a weighted, fixed effects linear regression of the log relative risks (or odds ratios) from the individual studies, with the inverse of the variance of log relative risks as the weights. To convert 95% confidence intervals (95% CIs) into estimates of the variance of the log relative risk (or odds ratio), we transformed the interval to the log scale. The absolute difference between the upper and lower end points was then divided by 3-92 to obtain an approximate SEM. The procedure was modified in reports that gave 90% GIs. 
Meta-analyses
The meta-analyses were performed separately for case-control and cohort studies. The stud- ies used different end points of cardiovascular disease. For the overall pooled analysis, one end point was selected for each study. These were in order of priority: total CHD (fatal CHD and non-fatal myocardial infarction), myocardial infarction (fatal or non-fatal), or fatal CHD (including sudden coronary death). As well as the main pooled analysis, three separate meta-analyses of cohort studies were carried out with CHD death, fatal or non-fatal myocardial infarction, and total CHD as end points. Studies that reported results for all three end points24 40 contributed data to each subanalysis.
Sensitivity analyses
We examined the sensitivity of the pooled results to the method of assigning cups/day to the open ended categories used for the highest intake of coffee. In this sensitivity analysis, we assigned the lowest number of cups in a particular category instead of the mean number of cups based on the Framingham distribution. Thus we assigned six cups to the category six or more cups/day (instead of 7-4 cups), and seven cups to the category seven or more cups/day (instead of 8-5 cups). Two studies reported on total cardiovascular disease events rather than coronary heart disease events.2945 The pooled analyses were repeated both including and excluding these two studies to examine the sensitivity of the results of studies with different end points.
As cigarette smoking is positively associated with coffee consumption,4849 failure to adjust for smoking results in a biased estimate of the risk of coronary heart disease. In our study, we performed a meta-analysis restricted to non-smokers, with data from a subsample of studies that reported data separately for smokers and non-smokers.
We next carried out a pooled analysis of the three case-control studies25 32 34 that included data on decaffeinated coffee. Only one cohort study provided data on decaffeinated coffee intake." We also carried out separate analyses for men and women to look for any sex differences in the effect of coffee on heart disease.
Results
GENERAL FINDINGS
Appendices to tables 1 and 2 show the characteristics of the case-control and cohort studies included in the meta-analysis. Of the eight case-control studies selected for metaanalysis, seven'5 30 32-35 37 reported a positive association (or a significant trend in risk) between coffee consumption and coronary heart disease. Of the 15 cohort studies included in the meta-analysis, five' 026 27 39 42 reported a positive association between coffee intake and risk of heart disease. REGRESSION 
RESULTS
Unless otherwise stated, all the pooled odds ratios (or relative risks) given are for the comparison of five cups of coffee/day v none. A log linear assumption was made, in which the estimated relative risk for five cups/day is the antilog of five times the coefficient for one cup (v none) shown on appendices to tables 1 and 2.
The pooled odds ratio for case-control studies was 1-63 (95% CI 1.50 to 1.78). The x2 for heterogeneity among case-control studies was 10-3 (degrees of freedom (df) 7, P > 0-1). For cohort studies, the pooled relative risk was 1-05 (95% CI 0-99 to 1-12). Due to the extremely high heterogeneity among the cohort studies (X2 = 85-4, df 14, P < 0'0001), the SEM for the pooled coefficients is almost certainly an underestimate. When the -regression procedures were repeated with the more conservative assignment of cups/day in the open ended categories, the pooled odds ratios or relative risks were virtually unchanged (table 1) .
We carried out separate pooled procedures for each of the end points: CHD death, myocardial infarction (fatal and non-fatal), and total CHD (table 2). These analyses were done only for cohort studies, as all the casecontrol studies used myocardial infarction as their end point (with the exception of the study by Hennekens et al,36 which used fatal CHD as the end point). The pooled relative risks were 0 97 (95% CI 0'94-1-01) for CHD death, 1-16 (95% CI 1-02 to 1-30) for myocardial infarction, and 1-25 (95% CI 1.08 to 1 46) for total CHD. These results suggest a possible slight increase in risk of coronary heart disease, although the magnitude of the effect is such that confoundingfor example, by smoking-could not be ruled out.
To compensate for confounding by smoking we next performed a pooled analysis restricted to data on non-smokers. Three case-control studies,25 34 35 and six cohort studies26373940 4245 included such data (table 3) . Among cohort studies there was no suggestion of increased risk (pooled relative risk = 1-04; 95% CI 0-71 to 1-52). The pooled result among case-control studies was again discrepant from the cohort data with a summary odds ratio among non-smokers of 1 85 (95% CI 1-42 to 2 42).
The pooled odds ratio from the three case- control studies that examined decaffeinated coffee was 1X42 (95% CI 1-01 to 1-99, X2 for heterogeneity = 0 9). This point estimate was not substantially different from the pooled odds ratio for caffeinated coffee (odds ratio = 1.65, 95% CI 1-52 to 1.81). We performed separate pooling procedures for men and women (table 4). The results for both case-control and cohort studies indicated similar magnitudes of effect of coffee drinking on risk of heart disease for men and women. The discrepancy between the results of case-control and cohort studies persisted.
Discussion
Our meta-analysis supersedes previous studies12 14 because it includes case-control studies (omitted in the study of Myers and Basinski12); pools data from a more comprehensive set of studies (15 cohort studies compared with 11 analysed in Myers and Basinski,12 and five by Greenland14); and stratifies the analyses by disease end point, smoking, and sex.
ASSESSMENT OF CAUSALITY Bradford Hill proposed a set of criteria by which to assess causality-namely, the strength, consistency, and specificity of the association found, the time relation between exposure and outcome, the existence of a biological gradient, and biological plausibility. 50 We consider each of these in turn.
Strength of association The pooled cohort study data suggest, at most, a very weak association (relative risk < 1 2) between coffee intake and risk of CHD. Even the pooled case-control data do not suggest a relative risk of CHD greater than about 1 6 for drinking five or more cups/day. Relative risks of this magnitude could easily arise from residual confounding by factors such as smoking, diet, and other cardiovascular risk factors.50 Coffee drinkers are more likely to smoke than those who do not drink coffee.48 49 Failure to adjust for cigarette smoking may thus lead to spurious associations between coffee drinking and CHD. Among studies that adjusted for smoking, sometimes substantial differences have been found between the crude age adjusted relative risks and the multivariate relative risks. For example, in the study by LaVecchia retrospective assessments of coffee intake. Data from cohort studies have shown the existence of recall bias when intake of other beverages (such as alcohol) are assessed retrospectively in relation to the onset of disease.5'
One limitation of the prospective study design is the lag time between exposure assessment and outcome, which might potentially obscure acute effects of coffee intake on risk of heart disease. '4 In cohort studies with repeated measurements of exposure assessment, the association between heart disease and coffee intake was strongest when the exposure measurement used was nearest to the outcome.'042 In the study by LaCroix et al the relative risk for five or more cups/day compared with none increased from 1-8 (95% CI 0-8 to 4 0) when intake was assessed 10 or more years previously, to 2-5 (95% CI 1-1 to 5 8) when the intake within the past five years was used.'0 Grobbee et al however, found no association between coffee intake and risk of heart disease, even though the mean lag time between exposure assessment and outcome was less than two years."I Evidence from the Nurses' Health Study suggests that coffee intake in an individual subject stays stable over time. 52 In this study, which assessed the reproducibility of food and beverage intake nine months apart, the Spearman correlation coefficient for coffee intake was 071, the highest recorded of all the items in the diet.
Biological gradient
The case-control data consistently suggest a monotonic dose-response gradient between daily coffee intake and risk of myocardial infarction. Compared with non-drinkers, those who drink five or six cups of coffee have about double the risk of myocardial infarction (relative risks of 2-2 reported by Rosenberg et al34; 2 1 by Rosenberg et al"5; 2-2 by Jick et al;30 2-1 by the Boston collaborative drug surveillance program35; and 1-86 by Mann and Thorogood33). In contrast, there was no overall suggestion of a biological gradient in the cohort data. In their meta-analysis of 11 cohort studies Myers and Basinski reported relative risks of 1 01 among drinkers of one to four cups/day, 1-01 for four to six cups/day, and 1-09 for six or more cups/day (with drinkers of less than one cup/day as the reference category).'2 Biological plausibility The biological plausibility of the association between coffee drinking and CHD is based, in part, on the effects of caffeine on the cardiovascular system. The available evidence, however, fails to implicate caffeine as such as a significant contributor to risk of cardiovascular disease.' Although the acute effects of caffeine on the cardiovascular system are well documented, it is doubtful that these are of sufficient clinical significance to produce CHD. Clinical data indicate that moderate caffeine consumption (< 500 mg/dayequivalent to four to six cups of coffee) does not increase the frequency or severity of car-diac arrhythmias, even among people with ischaemic heart disease or patients with preexisting ventricular extrasystoles. 30 3639 Both the prospective data by Grobbee et al,"1 and a pooled analysis of the three casecontrol studies that included data on decaffeinated coffee, suggest a marginally increased risk of CHD with decaffeinated coffee consumption. In the study by Grobbee et al the relative risk of total CHD with four or more cups of decaffeinated coffee consumed/day was 1-63 (95% CI 1-02 to 2 60), which may be attributable to an adverse effect of decaffeinated coffee on serum lipids."1 In one randomised trial, the consumption of three to six cups of decaffeinated coffee/day raised the concentrations of low density lipoprotein cholesterol.57
Boiled vfiltered coffee A biologically plausible hypothesis, not assessed by any of the epidemiological studies to date, is that the method of preparing coffee (boiling v filtering) affects the risk of cardiovascular disease. In a meta-analysis of 21 cross sectional studies, Bak found that filtered coffee was associated with an average increase in total cholesterol of 0-008 mmol/ldaily cup consumed, compared with an increase of 0-038 mmol/l for boiled (unfiltered) coffee.54
The studies from Sweden4" and Norway42 present an interesting comparison in this regard. In Norway, boiled coffee is the most common form of preparation, whereas in Sweden the predominant method of preparation is filtration. The Norwegian study by Tverdal et al found relative risks of CHD death (comparing more than nine v less than one cup/day) of 2-2 (95% CI 1 1 to 4 5) for men, and 5-1 (95% CI 0 4 to 60 3) for women.42 By contrast, the Swedish study reported a relative risk of CHD death (again comparing more than nine v less than one cup/day) of 1 1 (95% CI 0-5 to 2 4) for men.40 (A Norwegian cohort study that found no association between coffee drinking and CHD death has also been reported.'" Unlike the study by Tverdal et al2 this failed to exclude CHD cases at baseline; also, mortality data were obtained solely by linkage to the Norwegian Bureau of Statistics).
The adverse effect of coffee consumption on the lipid profile is now believed to stem from an as yet unidentified lipid soluble substance that is present in boiled preparations, but seems to be removed during the filtering process.58 Thus the precise measurement of coffee intake may be less relevant than the ascertainment of brewing method (filtered v boiled) in future epidemiological investigations of coffee intake and CHD. 25 Conversely, among cohort studies, there seems to be no consistent pattern whereby studies conducted before 1975 (the period during which there was relatively high prevalence of percolated coffee consumption) show a positive association between coffee intake and heart disease. The seven studies completed before 1975 show no association between coffee drinking and heart disease (pooled relative risk = 1 i03, 95% CI 0 94 to 1-12); whereas the four studies that assessed coffee drinking during the 1 980s reported a slightly positive association (pooled relative risk = 1-21, 95% CI 1-05 to 1-40).
In conclusion the pooled cohort data suggest very little association between coffee intake and risk of CHD. The pooled casecontrol data suggest an excess risk of the order of 60% for drinking five cups/day. The higher risk estimates from individual casecontrol studies may have resulted from a combination of bias in control selection30 35; recall bias; or be confounded by cigarette smoking3033 35; although it is unlikely that the discrepancy between cohort and case-control data could be wholly explained by bias ana confounding. It 
